[go: up one dir, main page]

KR102199871B1 - A process for preparing 3,11-Dichloro-6-methyl -6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide - Google Patents

A process for preparing 3,11-Dichloro-6-methyl -6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide Download PDF

Info

Publication number
KR102199871B1
KR102199871B1 KR1020180166904A KR20180166904A KR102199871B1 KR 102199871 B1 KR102199871 B1 KR 102199871B1 KR 1020180166904 A KR1020180166904 A KR 1020180166904A KR 20180166904 A KR20180166904 A KR 20180166904A KR 102199871 B1 KR102199871 B1 KR 102199871B1
Authority
KR
South Korea
Prior art keywords
methyl
dihydrodibenzo
dioxide
thiazepine
dichloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020180166904A
Other languages
Korean (ko)
Other versions
KR20200077733A (en
Inventor
오민근
김기남
변영석
박성태
조동호
Original Assignee
주식회사 한서켐
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 한서켐 filed Critical 주식회사 한서켐
Priority to KR1020180166904A priority Critical patent/KR102199871B1/en
Publication of KR20200077733A publication Critical patent/KR20200077733A/en
Application granted granted Critical
Publication of KR102199871B1 publication Critical patent/KR102199871B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D281/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02Seven-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 3,11-디클로로-6-메틸-6,11-디하이드로디벤조[c,f][1,2]티아제핀 5,5-디옥시드의 제조방법에 관한 것으로서, 좀 더 상세하게 설명하자면 염화아세틸과 동일 당량의 알코올 환경 하에서 in situ로 생성된 염화수소 기체를 사용하여 출발물질인 3-클로로-6-메틸-6,11-디히드로디벤조[c,f][1,2]티아제핀-11-올 5,5-디옥시드의 히드록시기를 염소기로 치환시킴으로서, 외부에서 과량의 염화수소 기체를 투입하지 않는 정량적 반응으로 안전한 분위기에서 고순도의 3,11-디클로로-6-메틸-6,11-디하이드로디벤조[c,f][1,2]티아제핀 5, 5-디옥시드를 고수율로 제조하는 방법에 관한 것이다.The present invention relates to a method for preparing 3,11-dichloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide, in more detail To explain, starting material 3-chloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2] by using hydrogen chloride gas generated in situ in an alcohol environment of the same equivalent as acetyl chloride. By substituting the hydroxy group of thiazepin-11-ol 5,5-dioxide with chlorine, it is a quantitative reaction that does not introduce excessive hydrogen chloride gas from the outside. High purity 3,11-dichloro-6-methyl-6, It relates to a method of preparing 11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide in high yield.

Description

3,11-디클로로-6-메틸-6,11-디하이드로디벤조[c,f][1,2]티아제핀 5,5-디옥시드의 제조방법{A process for preparing 3,11-Dichloro-6-methyl -6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide}Method for preparing 3,11-dichloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide{A process for preparing 3,11-Dichloro- 6-methyl -6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide}

본 발명은 3,11-디클로로-6-메틸-6,11-디하이드로디벤조[c,f][1,2]티아제핀 5,5-디옥시드의 제조방법에 관한 것으로서, 좀 더 상세하게 설명하자면 염화아세틸과 동일 당량의 알코올 환경 하에서 in situ로 생성된 염화수소 기체를 사용하여 출발물질인 3-클로로-6-메틸-6,11-디히드로디벤조[c,f][1,2]티아제핀-11-올 5,5-디옥시드의 히드록시기를 염소기로 치환시킴으로서, 외부에서 과량의 염화수소 기체를 투입하지 않는 정량적 반응으로 안전한 분위기에서 고순도의 3,11-디클로로-6-메틸-6,11-디하이드로디벤조[c,f][1,2]티아제핀 5, 5-디옥시드를 고수율로 제조하는 방법에 관한 것이다.The present invention relates to a method for preparing 3,11-dichloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide, in more detail To explain, starting material 3-chloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2] by using hydrogen chloride gas generated in situ in an alcohol environment of the same equivalent as acetyl chloride. By substituting the hydroxy group of thiazepin-11-ol 5,5-dioxide with chlorine, it is a quantitative reaction that does not introduce excessive hydrogen chloride gas from the outside. High purity 3,11-dichloro-6-methyl-6, It relates to a method of preparing 11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide in high yield.

본 발명의 목적물질인 3,11-디클로로-6-메틸-6,11-디하이드로디벤조[c,f][1,2]티아제핀 5,5-디옥시드는 다음 [반응식 1]에서 보는 바와 같이 항우울증 치료제인 티아넵틴 소듐(thianeptine sodium)의 제조 중간체로 매우 유용하게 사용되는 화합물이다. The target substance of the present invention, 3,11-dichloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide, is shown in the following [Scheme 1] As described above, it is a compound that is very useful as an intermediate for the production of tianeptine sodium, an antidepressant treatment.

[반응식 1][Scheme 1]

Figure 112018128845584-pat00001
Figure 112018128845584-pat00001

상기 티아넵틴 소듐은 Science Union & CIE에서 개발한 물질로서 1972년 프랑스에서 최초로 특허등록(FR 2104728)이 완료되었다. 티아넵틴 소듐은 항불안 작용과 재활력 효과(redynamizing effect)를 갖는 최초의 항우울증 치료제로서, 불안과 기분장애에서 두드러지게 나타나는 위장관계 징후 등을 포함하는 신체화 증상(somatic complaints)을 완화시키는 작용을 한다. 또한 알코올 중독과 약물 금단시에 나타나는 불안을 해소하고, 우울증 개선 및 정신적 고통과 육체적 증상을 완화시킨다. The tianeptine sodium is a material developed by Science Union & CIE, and the first patent registration (FR 2104728) in France was completed in 1972. Tianeptine sodium is the first antidepressant treatment with anti-anxiety and redynamizing effects, and has the effect of alleviating somatic complaints, including gastrointestinal signs that are prominent in anxiety and mood disorders. do. It also relieves anxiety that appears when alcoholism and drug withdrawal, improves depression, and relieves mental pain and physical symptoms.

종래에 알려진 3,11-디클로로-6-메틸-6,11-디하이드로디벤조[c,f] [1,2]티아제핀 5,5-디옥시드의 합성방법을 살펴보면, 현재까지 보고된 FR 2104728, EP 0671173, US 6441165, WO 2010/070667 등에서는 하기 [반응식 2]와 같이, 3-클로로-6-메틸-6,11-디히드로디벤조[c,f][1,2]티아제핀-11 -올 5,5-디옥시드를 염소로 치환된 용매에 현탁하고, 여기에 염화수소 기체를 투입하여 발포(bubbling) 시키는 치환반응이 보고되어 있다. Looking at the synthesis method of 3,11-dichloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide known in the prior art, FR reported so far 2104728, EP 0671173, US 6441165, WO 2010/070667, etc., 3-chloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine as shown in the following [Scheme 2]. A substitution reaction in which -11 -ol 5,5-dioxide is suspended in a solvent substituted with chlorine, and hydrogen chloride gas is added thereto to foam (bubbling) has been reported.

[반응식 2][Scheme 2]

Figure 112018128845584-pat00002
Figure 112018128845584-pat00002

상기 특허들에 소개된 종래의 방법은 염화수소 기체를 사용하는 고전적인 방법으로 반응공정의 진행이 간단하며 반응 완결 후 염화수소 기체의 제거가 용이한 장점이 있다. 그러나, 3-클로로-6-메틸-6,11-디히드로디벤조[c,f][1,2]티아제핀-11-올 5,5-디옥시드 현탁액에다 저온에서 2~4시간 동안 인체에 매우 유해한 독성물질인 염화수소 기체를 반응 종결시까지 지속적으로 투입하여 발포시켜야 하기 때문에 필요 이상의 염화수소 기체가 소비되는 문제가 있다.The conventional method introduced in the above patents is a classical method using hydrogen chloride gas, and has advantages in that the reaction process is simple and the hydrogen chloride gas is easily removed after completion of the reaction. However, 3-chloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-ol 5,5-dioxide suspension was added to the human body for 2-4 hours at low temperature. There is a problem in that more than necessary hydrogen chloride gas is consumed because hydrogen chloride gas, which is a very harmful toxic substance, must be continuously injected and foamed until the reaction is completed.

특히 대량 생산 시에는 과량의 염화수소 기체를 사용함으로 인해서 작업자의 건강과 안전에 심각한 문제를 야기할 우려가 있을 뿐만 아니라, 대기오염 및 폐기물 중화처리에 소요되는 비용 등으로 인해서 생산원가가 상승하는 문제가 있다.Particularly in mass production, there is a concern that serious problems may arise for the health and safety of workers due to the use of excessive hydrogen chloride gas, and production costs increase due to air pollution and costs for neutralizing waste. have.

FR 2104728FR 2104728 EP 0671173EP 0671173 US 6441165US 6441165 WO 2010/070667WO 2010/070667

따라서 본 발명이 해결하고자 하는 과제는 티아넵틴 소듐의 제조 중간체인 3,11-디클로로-6-메틸-6,11-디하이드로디벤조[c,f][1,2]티아제핀 5,5-디옥시드를 제조함에 있어서, 비양성자성 유기용매 하에서 정량의 염화아세틸과 동일 당량의 알코올을 사용하여 안전한 공정과 친환경적인 분위기에서 저렴한 비용으로 고순도의 목적물질을 고효율로 제조할 수 있는 새로운 제조방법을 제공하는 것이다.Therefore, the problem to be solved by the present invention is 3,11-dichloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-, an intermediate for producing tianeptine sodium. In the preparation of dioxide, a new manufacturing method that can produce high-purity target substances with high efficiency at low cost in a safe process and eco-friendly atmosphere by using the same equivalent amount of alcohol as acetyl chloride in a quantitative amount in an aprotic organic solvent. To provide.

본 발명에 따른 3,11-디클로로-6-메틸-6,11-디하이드로디벤조[c,f] [1,2]티아제핀 5,5-디옥시드의 제조방법은, (a) 3-클로로-6-메틸-6,11-디히드로디벤조[c,f][1,2]티아제핀-11-올 5,5-디옥시드를 비양성자성 유기용매에 현탁하는 단계와; (b) 상기 3-클로로-6-메틸-6,11-디히드로디벤조[c,f][1,2]티아제핀-11-올 5,5-디옥시드에 대하여 1~3당량의 알코올을 첨가하여 0~10℃로 냉각하는 단계와; (c) 0~10℃의 온도에서 다시 1~3당량의 염화아세틸을 적가(滴加)하고 25~35℃에서 교반하는 단계와; (d) 반응이 완료된 후 여과하여 아세톤으로 세척하는 단계; 를 포함하여 제조되는 것을 특징으로 한다.The method for preparing 3,11-dichloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide according to the present invention includes (a) 3- Suspending chloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-ol 5,5-dioxide in an aprotic organic solvent; (b) 1-3 equivalents of alcohol based on the 3-chloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-ol 5,5-dioxide Cooling to 0 ~ 10 ℃ by adding; (c) adding 1 to 3 equivalents of acetyl chloride dropwise at a temperature of 0 to 10°C and stirring at 25 to 35°C; (d) filtering and washing with acetone after completion of the reaction; It characterized in that it is manufactured, including.

본 발명은 출발물질인 3-클로로-6-메틸-6,11-디히드로디벤조[c,f] [1,2]티아제핀-11-올 5,5-디옥시드를 비양성자성 용매 하에서 정량의 염화아세틸과 동일 당량의 알코올 사용하여 치환반응 시킴으로서, 인체에 유해한 염화수소 기체를 다량 사용해야 하는 종래 방법에 비해 전반적인 공정이 매우 안전하게 개선되고, 나아가 목적물질의 수율이 약 10% 이상 향상되는 효과를 얻을 수 있다.In the present invention, the starting material 3-chloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-ol 5,5-dioxide is used in an aprotic solvent. By using a quantitative amount of acetyl chloride and the same equivalent of alcohol, the overall process is improved very safely and the yield of the target substance is improved by about 10% or more, compared to the conventional method in which a large amount of hydrogen chloride gas harmful to the human body is used. Can be obtained.

즉, 본 발명은 외부에서 염화수소 기체를 투입하여 발포시키는 것이 아니라, 반응 시스템 내에서 염화수소 기체가 생성되기 때문에 반응효율이 높다. 그리고, 정량적으로 염화수소기체를 생성시켜 반응에 참여하게 하여, 불필요한 염화수소기체의 사용을 자제함으로서 친환경적이며 안전하고 경제적으로 목적 물질을 제조할 수 있는 효과가 있다.That is, in the present invention, the reaction efficiency is high because hydrogen chloride gas is generated in the reaction system instead of foaming by introducing hydrogen chloride gas from the outside. In addition, by quantitatively generating hydrogen chloride gas to participate in the reaction, there is an effect that the target material can be manufactured eco-friendly, safe and economically by refraining from the use of unnecessary hydrogen chloride gas.

도 1은 본 발명의 실시예에 따라 제조된 3,11-디클로로-6-메틸-6,11-디하이드로디벤조[c,f][1,2]티아제핀 5,5-디옥시드의 고성능 액체 크로마토그래피이다.
도 2는 본 발명의 비교예에 따라 제조된 3,11-디클로로-6-메틸-6,11-디하이드디벤조[c,f][1,2]티아제핀 5,5-디옥시드의 고성능 액체 크로마토그래피이다.
도 3은 본 발명의 제조예에 따라 제조된 티아넵틴 소듐의 핵자기공명 스펙트럼이다.
1 is a high performance of 3,11-dichloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide prepared according to an embodiment of the present invention It is liquid chromatography.
Figure 2 is a high performance of 3,11-dichloro-6-methyl-6,11-dihydrdibenzo[c,f][1,2]thiazepine 5,5-dioxide prepared according to the comparative example of the present invention It is liquid chromatography.
3 is a nuclear magnetic resonance spectrum of tianeptine sodium prepared according to Preparation Example of the present invention.

본 발명에 따른 3,11-디클로로-6-메틸-6,11-디하이드로디벤조[c,f] [1,2]티아제핀 5,5-디옥시드의 제조방법은 다음 [반응식 3]으로 표시된다.The method for preparing 3,11-dichloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide according to the present invention is shown in [Scheme 3] Is displayed.

[반응식 3][Scheme 3]

Figure 112018128845584-pat00003
Figure 112018128845584-pat00003

본 발명에서는 먼저 출발물질인 3-클로로-6-메틸-6,11-디히드로디벤조[c,f][1,2]티아제핀-11-올 5,5-디옥시드를 비양성자성 용매에 현탁한다. 상기 비양성자성 용매로는 디클로로메탄, 1,2-디클로로에탄, 클로로포름, 메틸아세테이트, 에틸아세테이트, 아세톤, 에테르, 테트라하이드로퓨란, 아세토니트릴, 톨루엔 중에서 선택된 어느 하나 이상을 사용할 수 있으나, 이중에서 디클로로메탄을 사용하는 것이 가장 바람직하다.In the present invention, the starting material, 3-chloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-ol 5,5-dioxide, is first used as an aprotic solvent. Suspend in As the aprotic solvent, any one or more selected from dichloromethane, 1,2-dichloroethane, chloroform, methyl acetate, ethyl acetate, acetone, ether, tetrahydrofuran, acetonitrile, and toluene may be used. It is most preferred to use methane.

다음으로 상기 3-클로로-6-메틸-6,11-디히드로디벤조[c,f][1,2]티아제핀-11-올 5,5-디옥시드에 대하여 1~3 당량의 알코올을 첨가한다. 상기 알코올로는 메탄올, 에탄올, n-프로판올, 이소프로판올 중에서 선택된 어느 하나이상을 사용할 수 있으나, 이중에서 메탄올을 사용하는 것이 가장 바람직하다. Next, 1-3 equivalents of alcohol based on the 3-chloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-ol 5,5-dioxide Add. As the alcohol, any one or more selected from methanol, ethanol, n-propanol, and isopropanol may be used, but methanol is most preferably used.

다음으로 현탁 상태의 출발물질을 0~10℃로 냉각한 후, 다시 상기 3-클로로-6-메틸-6,11-디히드로디벤조[c,f][1,2]티아제핀-11-올 5,5-디옥시드에 대하여 1~3 당량의 염화아세틸을 천천히 투입한다. 이때, 상기 염화아세틸의 사용량은 앞서 투입한 알코올과 동일한 당량으로 사용하는 것이 바람직하다.Next, after cooling the suspended starting material to 0 ~ 10 ℃, the 3-chloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine-11- Slowly add 1 to 3 equivalents of acetyl chloride based on 5,5-dioxide. In this case, the amount of acetyl chloride is preferably used in the same amount as the previously added alcohol.

본 발명에서 상기 알코올이나 상기 염화아세틸의 사용량이 각각 1 당량 미만이면, 반응이 완결되지 않아서 수율이 감소한다. 반대로, 상기 알코올이나 상기 염화아세틸의 사용량이 각각 3 당량을 초과하면, 다량의 염화수소 기체가 방출됨으로 인한 환경오염과 작업자의 안전을 보장할 수 없으며, 기존의 제법과 비교하여 가격 대비 효율이 감소한다. In the present invention, if the amount of the alcohol or the acetyl chloride used is less than 1 equivalent, the reaction is not completed and the yield decreases. On the contrary, if the amount of alcohol or acetyl chloride used exceeds 3 equivalents each, environmental pollution and worker safety due to the release of a large amount of hydrogen chloride gas cannot be guaranteed, and the cost-effectiveness decreases compared to the existing manufacturing method. .

다음으로 상기 반응용액을 25~35℃에서 교반하여 반응 완결을 확인한다. 여기서 상기 온도가 25℃ 미만이면, 치환반응의 반응성이 낮아져 반응의 미완결로 인해 수율이 감소한다. 반대로 35℃를 초과하면, 반응용매 내부의 염화수소 기체의 용해도가 낮아져 반응의 미완결로 인해 수율이 감소한다.Next, the reaction solution is stirred at 25 ~ 35 ℃ to confirm the completion of the reaction. Here, if the temperature is less than 25° C., the reactivity of the substitution reaction decreases, and the yield decreases due to incomplete reaction. Conversely, if it exceeds 35°C, the solubility of hydrogen chloride gas in the reaction solvent decreases, and the yield decreases due to incomplete reaction.

마지막으로, 반응이 완결된 반응액을 0~5℃에서 숙성하여 여과, 아세톤 세척하여 본 발명의 목적물질인 3,11-디클로로-6-메틸-6,11-디하이드로디벤조[c,f][1,2]티아제핀 5,5-디옥시드를 수득한다.Finally, the reaction solution after the completion of the reaction was aged at 0~5℃, filtered, washed with acetone, and the target substance of the present invention, 3,11-dichloro-6-methyl-6,11-dihydrodibenzo[c,f ][1,2]thiazepine 5,5-dioxide is obtained.

이하, 본 발명에 대한 실시예를 들어보면 다음과 같다.Hereinafter, examples of the present invention will be described.

[실시예][Example]

50ml의 반응용기에 3-클로로-6-메틸-6,11-디히드로디벤조[c,f][1,2]티아제핀-11-올 5,5-디옥시드 5g을 넣고, 다음 [표 1]의 비양성자성 용매 25ml를 투입하였다. 이어 다음 [표 1]과 같이 알코올 1~3당량을 첨가한 뒤, 0~10℃로 냉각하였다. 상기 알코올과 동일 당량의 염화아세틸을 0~10℃의 온도에서 천천히 가하고, 25~35℃의 온도에서 교반하였다.In a 50 ml reaction vessel, 5 g of 3-chloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-ol 5,5-dioxide was added, and the following table 25 ml of the aprotic solvent of 1] was added. Then, after adding 1 to 3 equivalents of alcohol as shown in the following [Table 1], it was cooled to 0 to 10°C. Acetyl chloride in the same amount as the alcohol was slowly added at a temperature of 0 to 10°C, and stirred at a temperature of 25 to 35°C.

상기 반응이 완료된 반응액을 0~5℃로 냉각한 후, 교반 숙성하였다. 숙성된 고체를 여과한 다음, 아세톤으로 세척하여 백색의 고체상 목적물질인 3,11-디클로로-6-메틸-6,11-디하이드로디벤조[c,f][1,2]티아제핀 5,5-디옥시드를 수득하였다. 각 실시예 별로 확인된 목적물질의 수율은 다음 [표 1]과 같다. 참고로 다음 [표 1]에서 ‘AcCl’은 염화아세틸(Acetyl chloride)을 의미한다.After the reaction solution was cooled to 0 ~ 5 ℃ the reaction was completed, and aged with stirring. The aged solid was filtered, washed with acetone, and a white solid target material, 3,11-dichloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5, 5-dioxide was obtained. The yield of the target substance identified for each example is shown in Table 1 below. For reference, in the following [Table 1], “AcCl” means acetyl chloride.

실시예Example 알코올Alcohol 비양성자성
용매
Aprotic
menstruum
AcCl
사용 당량
AcCl
Equivalent
수율yield
종류Kinds 사용 당량Equivalent to use 1One 메탄올Methanol 2.02.0 디클로로메탄Dichloromethane 2.02.0 96 %96% 22 메탄올Methanol 1.21.2 디클로로메탄Dichloromethane 1.21.2 93 %93% 33 메탄올Methanol 3.03.0 디클로로메탄Dichloromethane 3.03.0 96 %96% 44 메탄올Methanol 1.01.0 디클로로메탄Dichloromethane 1.01.0 90 %90% 55 에탄올ethanol 2.02.0 디클로로메탄Dichloromethane 2.02.0 94 %94% 66 n-프로판올n-propanol 2.02.0 디클로로메탄Dichloromethane 2.02.0 94 %94% 77 iso-프로판올iso-propanol 2.02.0 디클로로메탄Dichloromethane 2.02.0 93 %93% 88 메탄올Methanol 2.02.0 아세톤Acetone 2.02.0 93 %93% 99 메탄올Methanol 2.02.0 1,2-디클로로에탄1,2-dichloroethane 2.02.0 94 %94% 1010 메탄올Methanol 2.02.0 에테르ether 2.02.0 92 %92% 1111 메탄올Methanol 2.02.0 테트라하이드로퓨란Tetrahydrofuran 2.02.0 93 %93% 1212 메탄올Methanol 2.02.0 아세토니트릴Acetonitrile 2.02.0 92 %92% 1313 메탄올Methanol 2.02.0 톨루엔toluene 2.02.0 93 %93% 1414 메탄올Methanol 2.02.0 메틸아세테이트Methyl acetate 2.02.0 92 %92% 1515 메탄올Methanol 2.02.0 에틸아세테이트Ethyl acetate 2.02.0 93 %93%

상기 표 1에서, 알코올과 염화아세틸의 사용 당량은 출발물질인 3-클로로-6-메틸-6,11-디히드로디벤조[c,f][1,2]티아제핀-11-올 5,5-디옥시드의 몰수에 대한 상대적 값을 나타낸다.In Table 1, the equivalent amount of alcohol and acetyl chloride used is 3-chloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-ol 5, which is a starting material, It represents the relative value for the number of moles of 5-dioxide.

[제조예 1][Production Example 1]

250ml의 반응용기에 50g의 디클로로메탄, 4.4g의 트리에틸아민, 3.6g의 에틸 7-아미노헵타노에이트 염산염을 넣고 용해하였다. 여기에다 상기 [표 1]의 [실시예 1]에 따라 제조된 3,11-디클로로-6-메틸-6,11-디하이드로디벤조[c,f][1,2]티아제핀 5,5-디옥시드 4.7g을 넣고, 8시간 환류 반응한 다음, 50g의 정제수로 세척하였다.In a 250 ml reaction vessel, 50 g of dichloromethane, 4.4 g of triethylamine, and 3.6 g of ethyl 7-aminoheptanoate hydrochloride were added and dissolved. In addition, 3,11-dichloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5- prepared according to [Example 1] of [Table 1] above. 4.7 g of dioxide was added, refluxed for 8 hours, and then washed with 50 g of purified water.

디클로로메탄 용액을 무수황산나트륨으로 건조한 다음, 감압농축하였다. 농축이 완료된 잔사에 20g의 메탄올을 넣어 희석하였다. 이 용액에 9% 수산화나트륨 수용액 8ml를 넣고, 3시간 동안 환류 반응하였다. 반응액을 감압 농축한 다음, 30g의 정제수로 희석하였다. 여기에 9% 묽은염산 8ml를 넣고, 디클로로메탄으로 추출하였다.The dichloromethane solution was dried over anhydrous sodium sulfate and then concentrated under reduced pressure. 20 g of methanol was added to the concentrated residue and diluted. To this solution, 8 ml of a 9% aqueous sodium hydroxide solution was added, followed by reflux reaction for 3 hours. The reaction solution was concentrated under reduced pressure, and then diluted with 30 g of purified water. To this, 8 ml of 9% diluted hydrochloric acid was added and extracted with dichloromethane.

디클로로메탄 용액을 무수황산마그네슘으로 건조한 다음, 감압농축하고, 30g의 메탄올을 넣어 결정화하였다. 석출된 결정을 여과하고, 메탄올로 세척하여 7-[[(11RS)-3-클로로-6-메틸-6,11-디하이드로디벤조[c,f][1,2]티아제핀-11-일]아미노]-헵탄산 S,S-디옥시드(수율: 80%, 순도: 99.88%)를 수득하였다.The dichloromethane solution was dried over anhydrous magnesium sulfate, concentrated under reduced pressure, and crystallized by adding 30 g of methanol. The precipitated crystals were filtered, washed with methanol, and 7-[[(11RS)-3-chloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine-11- Yl]amino]-heptanoic acid S,S-dioxide (yield: 80%, purity: 99.88%) was obtained.

[제조예 2][Production Example 2]

100ml의 반응용기에 25g의 메탄올과, 상기 [제조예 1]에서 제조한 7-[[(11RS)-3-클로로-6-메틸-6,11-디하이드로디벤조[c,f][1,2]티아제핀-11-일]아미노]-헵탄산 S,S-디옥시드 5g을 넣고 분산하였다. 0.5g의 수산화나트륨을 5g의 메탄올에 용해한 다음, 이를 상기 7-[[(11RS)-3-클로로-6-메틸-6,11-디하이드로디벤조[c,f][1,2]티아제핀-11-일]아미노]-헵탄산 S,S-디옥시드 현탁액에 가하여 1시간 동안 교반하였다. In a 100 ml reaction vessel, 25 g of methanol and 7-[[(11RS)-3-chloro-6-methyl-6,11-dihydrodibenzo[c,f][1] prepared in [Preparation Example 1] above. 5 g of,2]thiazepin-11-yl]amino]-heptanoic acid S,S-dioxide was added and dispersed. 0.5 g of sodium hydroxide was dissolved in 5 g of methanol, which was then 7-[[(11RS)-3-chloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thia Zepin-11-yl]amino]-heptanoic acid S,S-dioxide was added to the suspension and stirred for 1 hour.

얻어진 반응액을 감압 농축한 다음, 25g의 디클로로메탄으로 용해하고, 디에틸에테르를 가하여 결정화하였다. 석출된 결정을 여과하고, 디에틸에테르로 세척하여 티아넵틴 소듐(수율: 95%, 순도: 99.88%)을 수득하였다.The resulting reaction solution was concentrated under reduced pressure, dissolved in 25 g of dichloromethane, and crystallized by adding diethyl ether. The precipitated crystals were filtered and washed with diethyl ether to obtain tianeptine sodium (yield: 95%, purity: 99.88%).

[비교예 1][Comparative Example 1]

250ml의 반응용기에 10g의 3-클로로-6-메틸-6,11-디히드로디벤조[c,f][1,2]티아제핀-11-올 5,5-디옥시드를 넣고, 디클로로메탄 100ml를 투입하였다. 이어서 0~10℃로 냉각한 후, 염화수소 기체를 2~4시간 동안 투입하였다.In a 250 ml reaction vessel, 10 g of 3-chloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-ol 5,5-dioxide was added, and dichloromethane 100 ml was added. Subsequently, after cooling to 0-10° C., hydrogen chloride gas was added for 2-4 hours.

반응이 완결된 반응액을 여과하고, 디클로로메탄으로 세척하여 목적물질인 3,11-디클로로-6-메틸-6,11-디하이드로디벤조[c,f][1,2]티아제핀 5,5-디옥시드(수율: 83%)를 수득하였다. 참고로 상기 비교예는 앞서 종래 기술로 소개한 국제특허공개 WO2010/070667호에 기재된 방법으로 실시한 것이다.The reaction solution after the reaction was completed was filtered, washed with dichloromethane, and the target material, 3,11-dichloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5, 5-dioxide (yield: 83%) was obtained. For reference, the comparative example was carried out by the method described in International Patent Publication No. WO2010/070667 previously introduced in the prior art.

[고성능 액체크로마토그피 및 핵자기공명 스펙트럼 분석][High-performance liquid chromatograph and nuclear magnetic resonance spectrum analysis]

가. 고성능 액체크로마토그래피 분석end. High performance liquid chromatography analysis

상기 [실시예 1] 및 [비교예]에서 목적물질로 수득된 3,11-디클로로-6-메틸-6,11-디하이드로디벤조[c,f][1,2]티아제핀 5,5-디옥시드의 고성능 액체크로마토그래피(HPLC) 데이터를 분석하고, 그 결과를 첨부 [도 1] 및 [도 2]에 수록하였다.3,11-dichloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5 obtained as the target substance in the above [Example 1] and [Comparative Example] -Analyze the high performance liquid chromatography (HPLC) data of the oxide, and the results are included in the attached [Fig. 1] and [Fig. 2].

첨부 도 1 및 도 2에서 보는 바와 같이, 본 발명의 실시예에 따라 제조된 목적물질은 종래 방법인 비교예에 따라 제조된 목적물질과 피크 특성이 거의 동등한 결과를 보였다. 이때, 고성능 액체크로마토그래피(HPLC)의 측정조건은 유럽약전의 방법과 동일하게 진행하였다.As shown in Figs. 1 and 2, the target material prepared according to the embodiment of the present invention showed almost the same peak characteristics as the target material prepared according to the comparative example, which is a conventional method. At this time, the measurement conditions of high performance liquid chromatography (HPLC) were carried out in the same manner as in the European Pharmacopoeia.

나. 핵자기공명 스펙트럼 분석I. Nuclear magnetic resonance spectrum analysis

상기 제조예에 따라 합성한 티아넵틴 소듐에 대하여 핵자기공명(NMR) 데이터를 분석한 결과, 첨부 [도 3]에서 보는 바와 같이 d 7.77(s, 1H), 7.70(d, 2H), 7.49(m, 2H), 7.39(td, 1H), 7.34(td, 1H), 5.16(s, 1H), 3.50(s, 1H), 3.37(s, 3H), 2.67(s, 1H), 2.37(m, 2H), 1.84(t, 2H), 1.40(m, 4H), 1.17(m, 4H)에서 각각 피크를 보였다. As a result of analyzing nuclear magnetic resonance (NMR) data for tianeptine sodium synthesized according to the above preparation example, d 7.77 (s, 1H), 7.70 (d, 2H), 7.49 ( m, 2H), 7.39(td, 1H), 7.34(td, 1H), 5.16(s, 1H), 3.50(s, 1H), 3.37(s, 3H), 2.67(s, 1H), 2.37(m , 2H), 1.84 (t, 2H), 1.40 (m, 4H), 1.17 (m, 4H) showed peaks, respectively.

이때, 핵자기공명(NMR)의 측정조건은 다음과 같다.At this time, the measurement conditions for nuclear magnetic resonance (NMR) are as follows.

1) 장치 : Bruker Model DRX NMR 4001) Device: Bruker Model DRX NMR 400

2) 측정 범위: -1.0 ~ 15 ppm2) Measurement range: -1.0 ~ 15 ppm

3) 스캔 횟수: 163) Number of scans: 16

상기 실시예 및 비교예의 결과로부터 확인되는 바와 같이, 본 발명에 따른 3,11-디클로로-6-메틸-6,11-디하이드로디벤조[c,f][1,2]티아제핀 5,5-디옥시드의 제조방법은 불필요한 염화수소 기체의 사용을 자제함으로서 종래의 제조방법에 비해 전반적인 제조공정을 친환경적이고 안전하게 개선하고, 나아가 목적물질의 수율을 약 10% 이상 향상시킨 효과를 나타낸다.As can be seen from the results of Examples and Comparative Examples, 3,11-dichloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5 according to the present invention -The method of preparing the dioxide shows the effect of improving the overall manufacturing process environmentally and safely compared to the conventional manufacturing method by refraining from the use of unnecessary hydrogen chloride gas, and further improving the yield of the target substance by about 10% or more.

Claims (5)

(a) 3-클로로-6-메틸-6,11-디히드로디벤조[c,f][1,2]티아제핀-11-올 5,5-디옥시드를 디클로로메탄에 현탁하는 단계와;
(b) 상기 3-클로로-6-메틸-6,11-디히드로디벤조[c,f][1,2]티아제핀-11-올 5,5-디옥시드에 대하여 1~3 당량의 알코올을 첨가하여 0~10℃로 냉각하는 단계와;
(c) 0~10℃의 온도에서 상기 알코올과 동일한 당량의 염화아세틸을 적가(滴加)하고 25~35℃에서 교반하는 단계와;
(d) 반응이 완료된 후 여과하여 아세톤으로 세척하는 단계;
를 포함하여 제조되는 것을 특징으로 하는 3,11-디클로로-6-메틸-6,11-디하이드로디벤조[c,f][1,2]티아제핀 5,5-디옥시드의 제조방법.
(a) suspending 3-chloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-ol 5,5-dioxide in dichloromethane;
(b) 1 to 3 equivalents of alcohol based on the 3-chloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-ol 5,5-dioxide Cooling to 0 ~ 10 ℃ by adding;
(c) adding acetyl chloride in the same amount as the alcohol at a temperature of 0 to 10°C dropwise and stirring at 25 to 35°C;
(d) filtering and washing with acetone after completion of the reaction;
3,11-dichloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide, characterized in that prepared, including.
삭제delete 제1항에 있어서, 상기 (b)단계의 알코올로는, 메탄올, 에탄올, n-프로판올, iso-프로판올 중에서 선택된 어느 하나 이상을 사용하는 것을 특징으로 하는 3,11-디클로로-6-메틸-6,11-디하이드로디벤조[c,f][1,2]티아제핀 5,5-디옥시드의 제조방법.
The method of claim 1, wherein the alcohol in step (b) is 3,11-dichloro-6-methyl-6, characterized in that at least one selected from methanol, ethanol, n-propanol, and iso-propanol is used. ,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide production method.
삭제delete 삭제delete
KR1020180166904A 2018-12-21 2018-12-21 A process for preparing 3,11-Dichloro-6-methyl -6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide Active KR102199871B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020180166904A KR102199871B1 (en) 2018-12-21 2018-12-21 A process for preparing 3,11-Dichloro-6-methyl -6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020180166904A KR102199871B1 (en) 2018-12-21 2018-12-21 A process for preparing 3,11-Dichloro-6-methyl -6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide

Publications (2)

Publication Number Publication Date
KR20200077733A KR20200077733A (en) 2020-07-01
KR102199871B1 true KR102199871B1 (en) 2021-01-08

Family

ID=71601503

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020180166904A Active KR102199871B1 (en) 2018-12-21 2018-12-21 A process for preparing 3,11-Dichloro-6-methyl -6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide

Country Status (1)

Country Link
KR (1) KR102199871B1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105254587A (en) * 2015-10-21 2016-01-20 济南诚汇双达化工有限公司 Preparation method of tianeptine sodium intermediate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1269551A (en) 1969-03-27 1972-04-06 Science Union & Cie New tricyclic derivatives and process for their manufacture
FR2716623B1 (en) 1994-02-25 1996-08-23 Adir Use of a tricyclic derivative for obtaining medicaments intended for the treatment of mnemo-cognitive disorders.
FR2807039A1 (en) 2000-03-31 2001-10-05 Adir NOVEL PROCESS FOR THE PREPARATION OF 11-AMINO-3-CHLORO-6,11-DIHYDRO-5,5-DIOXO-6-METHYL-DIBENZO [c, f] [1,2] -THIAZEPINE AND APPLICATION TO THE SYNTHESIS OF TIANEPTINE
WO2010070667A2 (en) 2008-11-19 2010-06-24 Biophore India Pharmaceuticals Pvt. Ltd. Novel process for the preparation of 7-((3-chloro-6-methyl-5,5-dioxo-6,11-dihydrodibenzo(c,f)(1,2) thiazepin-11-yl)amino)heptanoate

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105254587A (en) * 2015-10-21 2016-01-20 济南诚汇双达化工有限公司 Preparation method of tianeptine sodium intermediate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Synthetic Communications, 1998, Vol.28, No.3, pp. 471-474*

Also Published As

Publication number Publication date
KR20200077733A (en) 2020-07-01

Similar Documents

Publication Publication Date Title
CN107793418A (en) Industrial production method of tofacitinib citrate
JP5873484B2 (en) Dronedarone and method for producing the salt thereof
CN102757431B (en) A kind of novel method of synthesizing sitagliptin
CN101353314A (en) Preparation of propacetamol hydrochloride
CN101863948B (en) High-purity (2 beta, 3 alpha, 5 alpha, 16 beta, 17 beta)-2-(4-morpholinyl)-16-(1-pyrrolidinyl)-androstane-3,17-diol or composition thereof and preparation method thereof
CN110590635A (en) Preparation method of levetiracetam and intermediate thereof
JP2021504418A (en) Method for producing 2- (5-methoxyisochroman-1-yl) -4,5-dihydro-1H-imidazole and its hydrogen sulfate
EP2397141A1 (en) Process for the synthesis of beta-amino acids and derivatives thereof
RU2405787C2 (en) Method for synthesis of 4beta-amino-4'-demethyl-4-desoxypodophyllotoxin
KR102199871B1 (en) A process for preparing 3,11-Dichloro-6-methyl -6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide
CN104974157A (en) Istradefylline synthesis process
CN106631828A (en) Preparation method of bromhexine hydrochloride
CN106243050B (en) A kind of method of suitable industrialized production Clobazam
CN113105335B (en) Synthetic method of stable deuterium-labeled melitracen hydrochloride
CN110804022B (en) Preparation method of dexrazoxane
CN104703967A (en) Method for purifying fluvoxamine free base and method for preparing highly pure fluvoxamine maleate using same
EA019735B1 (en) SYNTHESIS OF DIHYDROTHIENO[3,2-d]PYRIMIDINE DIOLS AND SIMILAR PYRIMIDINE DIOLS
CN106957235B (en) A kind of preparation method of tamoxifen
CN110759933A (en) Preparation method of cefdinir impurity G
CN115572262B (en) Isoquinoline derivative and preparation method thereof
CN102391170A (en) Method for preparing N,N-diallyl-5-methoxytryptamine hydrochlorides
KR102801536B1 (en) Preparation for Benzoamine derivatives
KR100982720B1 (en) Process for the preparation of 2-aminomalonamide as an intermediate for the production of 4-carbamoyl-1-β-D-ribofuranoslimidazolium-5-oleate
JP3899626B2 (en) Preparation of 2-mercaptothiazol
KR100958678B1 (en) Method for preparing cis-dimecrotinic acid and salts thereof

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20181221

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200828

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20201216

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210104

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210104

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240102

Start annual number: 4

End annual number: 4